PTPN11/Shp2 is currently being investigated as a novel therapy target in some hematologic malignancies and solid tumours [12,21,22], and recently, Shp2 inhibition was been shown to reduce tumour burden significantly in vivo in a metastatic breast cancer model [23]. The gene discussed is PTPN11; the disease is hematologic disorder.